GlassScriptPhysician profile
David Clump
NPI 1881868628
$17,296.38
in general payments reported to CMS, 2019-2025
16 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $122 · 2021: $1,605 · 2022: $12K · 2023: $2,352 · 2024: $428 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $10,929.69 | 2021-2024 | Reflexion Medical Radiotherapy System |
| Astrazeneca Pharmaceuticals LP | $4,498.40 | 2019-2025 | Onglyza |
| Eagle Pharmaceuticals, INC. | $500.00 | 2019 | |
| Elekta, INC. | $308.39 | 2022-2024 | Leksell Gamma Knife Icon |
| Siemens Medical Solutions USA, INC. | $294.71 | 2023 | Varian Treatment |
| Merck Sharp & Dohme LLC | $229.25 | 2025 | Keytruda |
| Celgene Corporation | $172.52 | 2019 | |
| Reprise Biomedical, INC. | $94.46 | 2024 | Miro3d, Mirotract, Miro3d Fibers |
| Genentech USA, INC. | $85.50 | 2024 | Phesgo |
| Eisai INC. | $77.63 | 2023 | |
| Kite Pharma, INC. | $59.86 | 2019 | |
| Amgen INC. | $29.61 | 2021 | |
| Genmab U.S., INC. | $16.36 | 2024 | Epkinly |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Clump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.